Edition:
United Kingdom

Stryker Corp (SYK.N)

SYK.N on New York Stock Exchange

161.28USD
19 Jan 2018
Change (% chg)

$1.00 (+0.62%)
Prev Close
$160.28
Open
$161.02
Day's High
$161.84
Day's Low
$160.72
Volume
555,991
Avg. Vol
354,578
52-wk High
$164.05
52-wk Low
$119.17

Select another date:

Tue, Jan 9 2018

BRIEF-Stryker Expects 2017 Adj Net Earnings Per Diluted Share To Be Toward High End Of Previous Range Of $6.45-$6.50​

* STRYKER - EXPECT 2017 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE TOWARD HIGH END OF PREVIOUSLY ANNOUNCED RANGE OF $6.45 TO $6.50​

BRIEF-Stryker Announces Howard Cox Jr Will Retire From Board

* STRYKER ANNOUNCES MR. HOWARD COX JR WILL RETIRE FROM BOARD OF DIRECTORS

Stryker beefs up ENT business with $662 million Entellus buy

Medical device maker Stryker Corp said on Thursday it would buy Entellus Medical Inc for $662 million, adding heft to its ear, nose and throat (ENT) business.

UPDATE 1-Stryker beefs up ENT business with $662 mln Entellus buy

Dec 7 Medical device maker Stryker Corp said on Thursday it would buy Entellus Medical Inc for $662 million, adding heft to its ear, nose and throat (ENT) business.

Stryker to buy Entellus Medical for $662 mln

Dec 7 Medical device maker Stryker Corp said on Thursday it would buy medical technology company Entellus Medical Inc in a deal valued at about $662 million, adding heft to its ENT business.

BRIEF-Stryker to buy Entellus Medical for $24.00/share in cash

* ENTELLUS MEDICAL ANNOUNCES DEFINITIVE AGREEMENT TO BE ACQUIRED BY STRYKER CORPORATION FOR A PURCHASE PRICE OF $24.00 PER SHARE IN CASH

BRIEF-Stryker declares $0.47 per share quarterly dividend

* STRYKER INCREASES DIVIDEND 11%, DECLARING A $0.47 PER SHARE QUARTERLY DIVIDEND Source text for Eikon: Further company coverage:

BRIEF-Stryker receives U.S. FDA HDE approval for the Neuroform Atlas stent system to treat wide neck aneurysms

* Stryker receives U.S. FDA HDE approval for the Neuroform Atlas™ stent system to treat wide neck aneurysms

BRIEF-Stryker Corp reports Q3 earnings per share $1.14

* Q3 earnings per share view $1.50 -- Thomson Reuters I/B/E/S

BRIEF-Stryker to acquire Vexim

* Stryker Corp - ‍Stryker paid EUR 20.00 per share and EUR 3.91 per BSAAR warrant for deal​

Select another date: